image
Healthcare - Drug Manufacturers - General - NASDAQ - US
$ 97.88
-4.8 %
$ 122 B
Market Cap
12.65
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one GILD stock under the worst case scenario is HIDDEN Compared to the current market price of 97.9 USD, Gilead Sciences, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one GILD stock under the base case scenario is HIDDEN Compared to the current market price of 97.9 USD, Gilead Sciences, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one GILD stock under the best case scenario is HIDDEN Compared to the current market price of 97.9 USD, Gilead Sciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GILD

image
$120.0$120.0$115.0$115.0$110.0$110.0$105.0$105.0$100.0$100.0$95.0$95.0$90.0$90.0$85.0$85.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
28.8 B REVENUE
6.04%
1.66 B OPERATING INCOME
-78.15%
480 M NET INCOME
-91.45%
10.8 B OPERATING CASH FLOW
35.25%
-3.45 B INVESTING CASH FLOW
-52.27%
-3.43 B FINANCING CASH FLOW
33.01%
6.67 B REVENUE
-11.92%
3.14 B OPERATING INCOME
28.26%
1.32 B NET INCOME
0.00%
1.76 B OPERATING CASH FLOW
-40.94%
-415 M INVESTING CASH FLOW
-84.44%
-3.43 B FINANCING CASH FLOW
-151.59%
Balance Sheet Gilead Sciences, Inc.
image
Current Assets 19.2 B
Cash & Short-Term Investments 11.6 B
Receivables 4.42 B
Other Current Assets 3.18 B
Non-Current Assets 39.8 B
Long-Term Investments 0
PP&E 5.41 B
Other Non-Current Assets 34.4 B
19.61 %7.49 %5.40 %9.18 %58.32 %Total Assets$59.0b
Current Liabilities 12 B
Accounts Payable 833 M
Short-Term Debt 1.82 B
Other Current Liabilities 9.36 B
Non-Current Liabilities 27.7 B
Long-Term Debt 24.9 B
Other Non-Current Liabilities 2.85 B
4.57 %23.54 %62.63 %7.17 %Total Liabilities$39.7b
EFFICIENCY
Earnings Waterfall Gilead Sciences, Inc.
image
Revenue 28.8 B
Cost Of Revenue 6.25 B
Gross Profit 22.5 B
Operating Expenses 20.8 B
Operating Income 1.66 B
Other Expenses 1.18 B
Net Income 480 M
30b30b25b25b20b20b15b15b10b10b5b5b0029b(6b)23b(21b)2b(1b)480mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
78.26% GROSS MARGIN
78.26%
5.78% OPERATING MARGIN
5.78%
1.67% NET MARGIN
1.67%
2.48% ROE
2.48%
0.81% ROA
0.81%
2.36% ROIC
2.36%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Gilead Sciences, Inc.
image
20b20b18b18b16b16b14b14b12b12b10b10b8b8b6b6b4b4b2b2b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 480 M
Depreciation & Amortization 2.77 B
Capital Expenditures -523 M
Stock-Based Compensation 835 M
Change in Working Capital -880 M
Others 6.75 B
Free Cash Flow 10.3 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Gilead Sciences, Inc.
image
Wall Street analysts predict an average 1-year price target for GILD of $94.1 , with forecasts ranging from a low of $71 to a high of $132 .
GILD Lowest Price Target Wall Street Target
71 USD -27.46%
GILD Average Price Target Wall Street Target
94.1 USD -3.82%
GILD Highest Price Target Wall Street Target
132 USD 34.86%
Price
Max Price Target
Min Price Target
Average Price Target
1401401301301201201101101001009090808070706060Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.71% DIVIDEND YIELD
0.79 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
3.503.503.003.002.502.502.002.001.501.501.001.000.500.500.000.000.430.520.570.630.680.710.730.750.770.790.430.470.520.570.630.680.710.730.750.770.790.430.470.520.570.630.680.710.730.750.770.431.720.471.930.522.130.572.340.632.570.682.750.712.860.732.940.753.020.773.100.792015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Gilead Sciences, Inc.
image
Sold
0-3 MONTHS
2.92 M USD 1
3-6 MONTHS
67.7 M USD 3
6-9 MONTHS
7.96 M USD 2
9-12 MONTHS
543 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable HDV RNA at end of treatment (EOT). In participants who sustained u. businesswire.com - 1 week ago
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical response in adults with PBC regardless of prior treatment history. Another analysis provides evidence supporting that Livdelzi delivered clinically and. businesswire.com - 1 week ago
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 2 weeks ago
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts In today's unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those that don't rely too heavily on international markets. marketbeat.com - 2 weeks ago
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss? GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure. zacks.com - 2 weeks ago
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com - 2 weeks ago
Gilead Sciences to Present at Upcoming Investor Conferences FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 13 at 11:20 AM Pacific Time RBC Capital Markets Global Healthcare Conference on Wednesday, May 21 at 11:30 AM Eastern Time Bernstein Annual Strategic Decisions Conference on Thursday, May 29 at 2:30 PM Eastern Time Jefferies Global Healthcare Conference on Wednesday, June 4 at. businesswire.com - 3 weeks ago
Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying kickbacks to doctors who agreed to prescribe its HIV drugs, the U.S. attorney's office in Manhattan said on Tuesday. reuters.com - 3 weeks ago
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions cnbc.com - 3 weeks ago
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, May 7-10, 2025, Amsterdam, furthering Gilead's commitment to transform the lives of people living with liver disease. New data to be presented at EASL will include a subgroup analysis from ASSURE, an ongoing open-label study, and an analysis of the Phase 3 RESPONSE trial and the open-label extension. Data w. businesswire.com - 3 weeks ago
Why Gilead Sciences Stock Slipped Today Gilead Sciences (GILD -2.85%) didn't have a bad first quarter, but investors didn't find it inspiring either. After publishing its earnings report after market close Thursday, the company saw its share price decline in excess of 2% the following day. fool.com - 3 weeks ago
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down. zacks.com - 3 weeks ago
8. Profile Summary

Gilead Sciences, Inc. GILD

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 122 B
Dividend Yield 0.71%
Description Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Contact 333 Lakeside Drive, Foster City, CA, 94404 https://www.gilead.com
IPO Date Jan. 22, 1992
Employees 17600
Officers Ms. Jacquie Ross C.F.A. Vice President of Investor Relations Dr. Linda Slanec Higgins Ph.D. Senior Vice President of Research, Innovation & Portfolio Dr. Flavius Martin M.D. Executive Vice President of Research Ms. Jyoti K. Mehra Executive Vice President of Human Resources Mr. Daniel P. O'Day Chairman & Chief Executive Officer Ms. Diane E. Wilfong Interim Corporate Controller, Chief Accounting Officer & Principal Accounting Officer Mr. Andrew D. Dickinson Chief Financial Officer Ms. Deborah H. Telman J.D. Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary Ms. Johanna Mercier Chief Commercial Officer Dr. Rudolf Ertl Senior Vice President of Commercial Operations of Australia, Canada, Europe